Indian Health Outcomes, Public Health and Economics Research Centre (IHOPE) Read More
Clinical Research
LVPEI has been successfully audited by United States - Food and Drug Administration Agency (US FDA) and European Medicine Agency (EMA) for performing clinical trials.
Raja Narayanan, Director, Clinical Research
Contact: 040 3061 2618
Mail: narayanan@lvpei.org
Kallam Anji Reddy Campus
Administrator: T. Charitha
Study Coordinators: Vijaya, Ramya, Kalpana, Kavya, SinduPriya
Study Optometrist: Manindra, Subba Rao
Contact Numbers (Clinical Research): 040-68102123/2124
Image reading centre:
Graders: Renuka Sai, Safia, Sushma
Contact Number: 040-6810 2170
Bhubaneswar Campus-Clinical Research
Clinical Research Coordinators: Asit, Satyaprakash
Ethics Committee Coordinator: Jeweel Mohapatra
Study Optometrists: Kartik Jana
Contact Number: 06740 2653261
GMRV Campus-Clinical Research
Clinical Research Coordinator: Sumitra, Aishwarya
Contact Number: 9515263101 / 9182211204
KAR CAMPUS |
|||||
|---|---|---|---|---|---|
| S.No | Name of the project | Principal Investigator | Supported By | Duration | CTRI |
| 1 | Long-term effects of semaglutide on diabetic retinopathy in subjects with type 2 diabetes (FOCUS) | Dr.Padmaja Kumari | Novanordisk | 2020-2025 | http://ctri.nic.in |
| 2 | A Phase Iiib/iv, Multicenter, Open-label, Single-arm Study To Investigate The Efficacy And Safety Of Faricimab (ro6867461) In Patients With Polypoidal Choroidal Vasculopathy | Dr.Raja Narayanan | Roche Products PVT Ltd | 2024-2025 | http://ctri.nic.in |
| 3 | A Phase III, Randomized, Double blind, Parallel Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity between Test Aflibercept and Eylea® in Patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD) | Dr.Ritesh Narula | Zydus | 2024-2025 | http://ctri.nic.in |
| 4 | A phase iii, multicenter, randomized, double masked, sham-controlled study to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ro7200220 administered intravitreally in patients with uveitic macular edema | Dr.Mudit Tyagi | Roche Products PVT Ltd | 2024-2025 | http://ctri.nic.in |
| 5 | A Phase IIa, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared with Vehicle in Subjects with Fuchs Endothelial Corneal Dystrophy (FECD) – PHANTOM Study | Dr.Sunita Chaurasia | SANTEN | 2023-2025 | http://ctri.nic.in |
| 6 | A Prospective, Randomized, Multicenter, Masked, Pivotal Study to Assess the Safety and Effectiveness of BYNOCS DAT (Dichoptic Amblyopia Training) Game in Treating Children with Amblyopia | Dr.Sampada Kulkarni | BYNOCS | 2024-2025 | http://ctri.nic.in |
| 7 | An Open-label, Prospective, randomized, multi-center, clinical trial designed to evaluate the Clinical Outcomes with Digital Workflow solutions versus conventional Workflow solution on postoperative refractive outcomes among patients undergoing cataract surgery with Toric intraocular lens. | Dr.Merle Fernandas | Carl Zeiss | 2024 | http://ctri.nic.in |
| 8 | A phase 3 multicentre, double masked, Randomised, study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with Aflibercept, compared with Aflibercept alone in patients with neovascular age related macular degeneration. | Dr.Vivek Dave | OPTHEA | 2023-2025 | http://ctri.nic.in |
| 9 | A Phase III, Prospective, Randomized, Parallel group, Double-blind, Multicentre Study to Compare the Efficacy, Safety, and Immunogenicity of Lupin’s Aflibercept with Eylea® in Patients with Neovascular Age-Related Macular Degeneration. LRP/LUBT017/2021/003 | Dr.Vishal Raval | LUPIN | 2024-2025 | http://ctri.nic.in |
| 10 | A Phase 1/2a Multi-Center, Dose-Escalation, Dose-Expansion Study to Evaluate the Safety and Efficacy of Eyecyte-RPETM when administered as a Single-dose Subretinal Injection in Subjects with Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (d-AMD) | Dr.Raja Narayanan | EyeStem | 2024-2025 | http://ctri.nic.in |
MTC CAMPUS |
|||||
|---|---|---|---|---|---|
| S.No | Name Of The Project | Principal Investigator | Supported By | Duration | CTRI |
| 1 | A phase 3 multicentre, double masked, Randomised, study to evaluate the efficacy and safety of intravitreal OPT-302 in combination with Aflibercept, compared with Aflibercept alone in patients with neovascular age related macular degeneration. | Dr.Tapas Ranjan | IQVIA | 2023-2025 | http://ctri.nic.in |
| 2 | A Prospective, Randomized, Multicenter, Masked, Pivotal Study to Assess the Safety and Effectiveness of BYNOCS DAT (Dichoptic Amblyopia Training) Game in Treating Children with Amblyopia | Dr.Debasmita | BYNOCS | 2024-2025 | http://ctri.nic.in |
GMRV CAMPUS |
|||||
|---|---|---|---|---|---|
| S.No | Name of the Project | Principal Investigator | Supported By | Duration | CTRI |
| 1 | A Prospective, Randomized, Multicenter, Masked, Pivotal Study to Assess the Safety and Effectiveness of BYNOCS DAT (Dichoptic Amblyopia Training) Game in Treating Children with Amblyopia | Dr.Virender Sachdeva | BYNOCS | 2024-2025 | http://ctri.nic.in |
| 2 | A Phase III, Prospective, Randomized, Parallel group, Double-blind, Multicentre Study to Compare the Efficacy, Safety, and Immunogenicity of Lupin’s Aflibercept with Eylea® in Patients with Neovascular Age-Related Macular Degeneration. LRP/LUBT017/2021/003 | Dr.Bhavik Panchal | LUPIN | 2024-2025 | http://ctri.nic.in |